AB 634 adds a new chapter to the California Health and Safety Code that makes it unlawful to manufacture, sell, deliver, distribute, hold, or offer for sale within the state any product that contains tianeptine. The prohibition is written broadly and applies to any product that contains the substance, regardless of product type or intended use.
The bill authorizes enforcement actions by the Attorney General and specified local prosecutors and provides civil penalties and fee-shifting for a prevailing plaintiff. For compliance teams and counsel, the measure creates a bright-line exclusion for tianeptine in the California marketplace and will force product reviews, supply‑chain controls, and platform moderation decisions for firms handling consumer health products.
At a Glance
What It Does
AB 634 outlaws the manufacture, sale, delivery, distribution, holding, or offer for sale in California of any product that contains tianeptine. It treats every product containing the substance as a violation and authorizes civil enforcement by the state Attorney General and certain local prosecutors.
Who It Affects
Manufacturers, distributors, and retailers of dietary supplements, nootropics, and other consumer health products; e-commerce platforms and marketplaces that list or ship products into California; and public prosecutors who will carry out enforcement. Testing labs and compliance officers will also be indirectly affected because of new screening needs.
Why It Matters
This is a single‑ingredient statewide ban rather than a labeling or disclosure rule—companies cannot lawfully offer products with tianeptine in California. It sets a compliance baseline that will change procurement, quality-control, and moderation practices, and raises questions about interplay with federal regulation and interstate e‑commerce.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
AB 634 writes a simple, categorical rule into California law: any product that contains tianeptine may not be manufactured, sold, distributed, held, or offered for sale in the state. The statutory language is broad and applies to any ‘‘product’’ without narrowing to supplements, foods, or drugs; under the bill, the presence of tianeptine in the product triggers a violation regardless of how the product is marketed.
Enforcement is limited to public authorities named in the statute: the Attorney General, a city attorney, a county counsel, or a district attorney. The bill makes those offices the exclusive private civil enforcers and provides that a prevailing plaintiff may recover reasonable attorney’s fees and costs.
It also states that the remedies in the chapter are cumulative with other legal remedies, preserving related claims under other laws.The text does not include exemptions or carve‑outs for licensed medical uses, research activities, or regulated pharmaceutical distribution, nor does it define de minimis thresholds for incidental or trace amounts. Because the prohibition applies to ‘‘offer for sale in this state,’’ listings and offers made over the internet and targeted at California residents are implicated; sellers, marketplaces, and payment processors will need to evaluate whether listings are offered in California and take steps to prevent prohibited sales.Practically speaking, compliance will require product testing and supply‑chain controls to ensure that ingredients and finished goods are free of tianeptine, updates to contracts with suppliers, and changes to marketplace moderation policies.
For public-enforcement offices, the statute creates a civil tool to remove prohibited products from commerce and recover enforcement costs, but it leaves open technical questions about proving presence, handling trace contamination, and coordinating with federal regulators.
The Five Things You Need to Know
The bill makes it unlawful to manufacture, sell, deliver, distribute, hold, or offer for sale in California any product that contains tianeptine — broad verbs that cover production, possession, and offers to transact.
Every product that contains tianeptine is explicitly deemed a violation; the statute creates strict‑liability exposure based on the presence of the substance rather than intent or marketing claims.
Only public prosecutors may bring civil actions under the chapter: the Attorney General, a city attorney, a county counsel, or a district attorney may seek penalties and other relief.
Civil penalties are statutorily capped at up to $2,500 for a first violation and up to $5,000 for each subsequent violation, as reflected in the bill text.
A prevailing plaintiff in an enforcement action is entitled to reasonable attorney’s fees and costs, and the bill makes its remedies cumulative with other available legal claims.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Core prohibition — manufacture, sale, distribution, possession, and offers
This subsection lists the prohibited acts: manufacturing, selling, delivering, distributing, holding, or offering for sale in California any product that contains tianeptine. The choice of verbs is important: ‘‘offer for sale’’ and ‘‘hold’’ extend liability beyond completed transactions to listings, advertising, and inventory, which matters for marketplaces, warehouses, and advertisers. Legal exposure therefore attaches to the act of making a product available to the California market, not only to consummated sales.
Strict‑liability trigger — any product containing tianeptine
This clause declares that every product that contains tianeptine ‘‘shall constitute a violation’’ of the prohibition. That language functions as a strict‑liability standard: the statute does not condition liability on knowledge, intent, or marketing claims. The practical effect is that defendants will have to show absence of tianeptine (for example through testing) rather than the state proving wrongful intent.
Enforcement and civil penalties
This subsection authorizes civil enforcement actions by the Attorney General, a city attorney, a county counsel, or a district attorney and sets monetary penalties for violations. Because only public prosecutors may sue, the bill creates a public‑sector enforcement regime rather than a private right of action. The availability of penalties gives prosecutors a remedial tool to seek monetary relief and deter sellers, but the statute does not create criminal penalties or administrative recall procedures.
Cumulative remedies and preservation of other claims
The bill explicitly states that its remedies do not preclude other legal causes of action and that the chapter’s remedies are cumulative. That preserves parallel enforcement under other state laws (for example, false advertising, consumer protection, or existing drug and food statutes) and allows prosecutors to pursue multiple theories against defendants offering prohibited products.
Fee‑shifting for prevailing plaintiffs
This provision entitles a prevailing plaintiff to reasonable attorney’s fees and costs. In practice, that strengthens public prosecutors’ financial footing to bring cases because it permits recovery of legal expenses, and it may influence charging and settlement dynamics. The provision applies to the public plaintiffs identified in the enforcement subsection rather than creating a private fee‑shifting mechanism for third‑party private litigants.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Consumers at risk of tianeptine exposure — a statewide ban reduces the legal availability of products containing tianeptine within California and can lower accidental or intentional consumer exposures.
- State and local public health and enforcement offices — prosecutors gain a civil statutory tool with fee‑shifting to remove prohibited products from the market and recover enforcement costs.
- Hospital emergency departments and first‑responders — by reducing availability the law may lower incidents requiring acute treatment related to tianeptine, easing some downstream clinical burden.
Who Bears the Cost
- Manufacturers and distributors of dietary supplements, nootropics, or unregulated wellness products — they must screen ingredients, rework supply chains, and remove noncompliant products from the California market.
- E‑commerce platforms and marketplaces — platforms will need enhanced listing controls, geoblocking or removal procedures for products offered to California consumers, and potentially more intensive seller vetting and testing requirements.
- Local prosecutorial offices — although empowered to sue, city attorneys and district attorneys may face increased caseloads and associated investigative costs, particularly around product testing and multi‑jurisdictional sellers.
Key Issues
The Core Tension
The central tension is between a bright‑line public‑health ban aimed at removing a specific hazardous ingredient from consumer commerce and the legal and practical difficulties that come with a categorical prohibition — namely, how to define and prove ‘‘contains,’’ how to avoid unintended interference with legitimate medical or research uses and federal regulation, and how to allocate enforcement burdens against dispersed, often online, supply chains.
The bill presents several implementation challenges and open questions. First, the statute offers no definition of ‘‘contains’’ or any de minimis threshold, leaving uncertainty about how trace contamination or cross‑contact in manufacturing will be treated.
Compliance and enforcement will likely hinge on laboratory testing standards, chain‑of‑custody rules, and litigation over what quantitative presence constitutes a violation.
Second, the text contains no express carve‑out for prescription drugs, clinical research, or controlled therapeutic uses. That omission raises preemption and coordination issues with federal regulators (for example, the FDA) and with existing state pharmacy and medical‑practice regulation.
Prosecutors and regulated parties will need to reconcile this categorical ban with other regulatory frameworks, and courts may be asked to resolve tensions between state‑level ingredient bans and federal drug oversight.
Finally, the statute's enforcement design concentrates authority in public prosecutors and provides fee recovery to prevailing plaintiffs, which may alter enforcement priorities but also create resource strains. The caps on civil penalties are modest and may be insufficient to deter large or out‑of‑state sellers; at the same time, fee‑shifting could incentivize aggressive enforcement actions.
The bill also leaves open how it will apply to online offers originating outside California but accessible to California consumers, which will require factual inquiries into targeting and marketplace controls.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.